Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.80), $0.94 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $175.82 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.